Država: Irska
Jezik: angleščina
Source: HPRA (Health Products Regulatory Authority)
PARICALCITOL
Abbott Laboratories Ireland Ltd
5 Microgram/ML
Solution for Injection
2005-04-08
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Zemplar 5 microgram/ml Solution for Injection. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of solution for injection contains 5 micrograms of paricalcitol. Each 1 ml ampoule contains 5 micrograms of paricalcitol. Each 2 ml ampoule contains 10 micrograms of paricalcitol. Excipients: Ethanol (20% v/v) and propylene glycol (30% v/v) For a full list of excipients see section 6.1. 3 PHARMACEUTICAL FORM Solution for Injection A clear and colourless aqueous solution. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism in patients with chronic renal failure undergoing haemodialysis. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Zemplar solution for injection is administered via haemodialysis access. Adults 1) Initial Dose should be calculated based on baseline parathryroid hormone (PTH) levels: The initial dose of paricalcitol is based on the following formula: Initial dose (micrograms) = baseline intact PTH level in pmol/l 8 OR = baseline intact PTH level in pg/mL 80 and administered as an intravenous (IV) bolus dose no more frequently then every other day at any time during dialysis. The maximum dose safely administered in clinical studies was as high as 40 micrograms. IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 21/07/2011_ _CRN 2091101_ _page number: 1_ 2) Titration Dose: The currently accepted target range for PTH levels in end-stage renal failure subjects undergoing dialysis is no more than 1.5 to 3 times the non-uremic upper limit of normal, 15.9 to 31.8 pmol/l (150-300 pg/ml), for intact PTH. Close monitoring and individual dose titrati Preberite celoten dokument